Overview

* ProQR Q2 revenue and EPS miss analysts' expectations, per LSEG data

* Co submitted CTA for AX-0810, targeting NTCP for cholestatic diseases

* ProQR holds EUR119.8 mln cash, providing runway into mid-2027

Outlook

* ProQR expects initial AX-0810 Phase 1 data in Q4 2025

* Company anticipates AX-2402 clinical candidate selection in 2025

* ProQR's cash runway extends into mid-2027, excluding Lilly milestones

Result Drivers

* LILLY PARTNERSHIP - Achieved milestones in collaboration with Eli Lilly, contributing €1.8 mln to revenue

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss EUR 3.82 EUR 4.45

Revenue mln mln (7

Analysts

)

Q2 EPS Miss -EUR -EUR

0.12 0.08 (7

Analysts

)

Q2 Net Miss -EUR -EUR

Income 12.18 8.99 mln

mln (6

Analysts

)

Q2 Miss -EUR -EUR

Operatin 12.25 8.77 mln

g Income mln (5

Analysts

)

Q2 Basic -EUR

EPS 0.12

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for ProQR Therapeutics NV ( PRQR ) is $9.00, about 77.1% above its August 6 closing price of $2.06

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)